No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy

Helle Zacho, Mads R Jochumsen, Niels C Langkilde, Jesper C Mortensen, Christian Haarmark, Helle W Hendel, Jørgen B Jensen, Lars J Petersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

OriginalsprogEngelsk
TidsskriftJournal of Nuclear Medicine
Vol/bind60
Udgave nummer12
Sider (fra-til)1713-1716
Antal sider4
ISSN0161-5505
DOI
StatusUdgivet - dec. 2019

Fingerprint

Sodium Fluoride
Radionuclide Imaging
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Prostatectomy
Cohort Studies
Prospective Studies

Citer dette

@article{08f59c2813464be184ce919e0e070ebb,
title = "No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy",
abstract = "The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93{\%}) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2{\%}), was equivocal in 7 patients (8.6{\%}), without bone metastases in 73 patients (90.1{\%}). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.",
author = "Helle Zacho and Jochumsen, {Mads R} and Langkilde, {Niels C} and Mortensen, {Jesper C} and Christian Haarmark and Hendel, {Helle W} and Jensen, {J{\o}rgen B} and Petersen, {Lars J}",
note = "{\circledC} 2019 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2019",
month = "12",
doi = "10.2967/jnumed.119.229062",
language = "English",
volume = "60",
pages = "1713--1716",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "12",

}

No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy. / Zacho, Helle; Jochumsen, Mads R; Langkilde, Niels C; Mortensen, Jesper C; Haarmark, Christian; Hendel, Helle W; Jensen, Jørgen B; Petersen, Lars J.

I: Journal of Nuclear Medicine, Bind 60, Nr. 12, 12.2019, s. 1713-1716.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy

AU - Zacho, Helle

AU - Jochumsen, Mads R

AU - Langkilde, Niels C

AU - Mortensen, Jesper C

AU - Haarmark, Christian

AU - Hendel, Helle W

AU - Jensen, Jørgen B

AU - Petersen, Lars J

N1 - © 2019 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2019/12

Y1 - 2019/12

N2 - The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

AB - The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

U2 - 10.2967/jnumed.119.229062

DO - 10.2967/jnumed.119.229062

M3 - Journal article

C2 - 31147402

VL - 60

SP - 1713

EP - 1716

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 12

ER -